Management Team - Segra International
Segra International is a plant biotechnology company that specializes in industrial-scale cannabis plant micropropagation. The company is developing industrial-scale cannabis micropropagation laboratories to produce healthy, robust plantlets for licensed cannabis producers globally.
Segra, Cannabis Micropropagation, Cannabis Tissue Culture, Research and Development, R&D, Quality Management Systems, facilities, plant-based medicines, medicinal, Cannabis, botanical, tissue culture, specialist, Genotyping Services, Tissue Culture Production, Modular Growing Facility, Micropropagation
15
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15,ajax_fade,page_not_loaded,,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive
 

Management Team

World-class scientific team, management team, and advisory board.

Segra has assembled a world-class team that consists of an extremely well-rounded group of academics, growers/breeders, managers, advisors, and financial executives. The Company also possesses an Advisory Board comprised of leading experts in the areas of clinical research, plant science, analytical chemistry, marketing, business and engineering.

Todd McMurray

CEO, President, Director

Mr. McMurray has been the President of Segra Biogenesis for 4 years and CEO of Segra International since its inception 1.5 years ago.  He is a business and corporate development professional with over 26 years of experience planning and financing the strategic initiatives of public and private companies including 4.5 years of experience in the cannabis industry. His background includes over 20 years as a director and/or senior officer of Canadian listed companies.

John Meekison

CPA, CMA, P.Log, CIM, BA, Chief Financial Officer

John Meekison, BA, CIM, – Mr. Meekison is a veteran investment banker specializing in life sciences at Loewen Ondaatje McCutcheon, Haywood Securities, Dlouhy Merchant and PI Securities. As a financier, Mr. Meekison has raised equity capital for various biotechnology companies such as StressGen Biotechnologies, ID Biomedical, Acorda Therapeutics, Inex Pharmaceuticals, Xenon Pharmaceuticals, Nortran Pharmaceuticals (now Cardiome) and BioMS Medical Corp. As CFO for a TSE listed company developing a novel clinical diagnostic platform, Mr. Meekison supervised all public reporting functions, human resources, accounting and budgeting, raising equity capital, renegotiating the Company’s existing line of credit, reviewing corporate strategy, and leading merger and acquisition (M&A) discussions. Mr. Meekison sits on the Board of Directors of Pacific Cascade Minerals Inc., Ravenstar Ventures Inc., and Natcore Technology Inc. Mr. Meekison received his BA from the University of British Columbia and is a Certified Investment Manager.

Dr. Sma Zobayed

Ph.D., Director of Tissue Culture

Dr. Zobayed is a leading specialist in tissue culturing with extensive international experience. Dr. Zobayed holds two patents relating to tissue culturing and has published over 50 scientific papers related to his research in the field. He holds a Ph.D. in Plant Tissue Culture, from the Department of Biological Sciences, University of Hull (UK), and has won awards for his tissue culture work from the scientific community. He is a member in good standing with the International Society of Arboriculture, International Association for Plant Tissue Culture and the International Society for Horticultural Sciences.

Ian Davidson

Chief Marketing Officer

Mr. Davidson is the Founder and President of Davidson Organics, a California-based agricultural consulting and project management company.  Over the past two years, Davidson Organics has developed more than four acres of certified organic compliant medical cannabis production in collaboration with large scale glass greenhouse flower producers in southern California. In 2007, Mr. Davidson founded Biologic Systems, a wholesale farm supply company, that has been a resource for organic farmers and medical cannabis producers across the West Coast.  From 2013 to 2016, Mr. Davidson was the Director of Agronomy for Bio-logical Capital in Hawaii, where he developed and managed livestock, conservation, and certified organic farming operations at the historic 3600-acre Hana Ranch.

Ryan Tiberti

Chief Operations Officer

Mr. Tiberti has developed, built, fund-raised, and operated several multi-million dollar licensed cannabis companies in Colorado and Nevada. He founded and was CEO of Well Grown, a successful cannabis consulting company serving other companies as well as investors across the United States. Previously, Ryan co-founded Home Automation Labs, a luxury home automation company specializing in smart home technology and automation, was the CMO for a specialized recruiting firm focusing on tech startups, and as a commercial real estate agent with J.A. Kennedy Real Estate Company. Ryan holds a B.A. in Finance from the University of Southern California’s Marshall School of Business. He also holds both a Nevada Real Estate License and is L.E.E.D. accredited.

Dr. Brian Toyota

MD, CM, MSc, FRCSC, Director

Dr. Toyota obtained his Medical Degree (MD) at McGill University, completed his neurosurgical residency at the University of Western Ontario and moved to B.C. in 1993. He began work at St. Paul’s Hospital before moving to Vancouver General Hospital (VGH) and the BC Cancer Agency (BBCA), in 1996. He was the Residency Program Director from 1995 – 2003; Co-Chair of the BCCA/Vancouver Stereotactic Radiosurgery Program from its inception in 1997 – 2013; Provincial Chair of Neuro-oncology for the BCCA 2004 – 2013 and President of the Canadian Neurosurgical Society 2012 – 2014. He is also on the editorial board of the Canadian Journal of Neurosciences and sits on the Royal College Specialty Committee for Neurosurgery and the Board of the American Association of Neurological Surgery.

Dr. Brian D. Toyota is a world-renowned medical and cancer expert, and the current Head of Neurosurgery at the University of British Columbia.

Chris Weidling

Director

Mr. Weidling is the sole proprietor of Weid Capital, a cannabis-focused financial consulting business. Prior to forming Weid Capital, Mr. Weidling consulted on or helped finance multiple cannabis businesses in the U.S. and Canada, including 2+ years as the CFO of Theraplant in Connecticut.

Dr. John Brunstein

Chief Scientific Officer

Dr. Brunstein obtained his Ph.D. in Biochemistry from the University of British Columbia in 1997, working on the molecular biology of viruses. Since then he has has worked with credible organizations including UBC as a Clinical Assistant Professor and later became the Chief Scientific Officer at the Centre for Translational and Applied Genomics. Dr. Brunstein has primarily worked through the company he founded, PathoID, as a consultant on biotechnology, molecular biology, and clinically related topics including clinical trials, assay validation methods, and quality systems in regulated industries for industrial and clinical sites in the US, Canada, and China. Dr. Brunstein has a broad exposure to biochemical analytical and molecular methods, quality systems, application of ISO/Health Canada/FDA and similar regulatory frameworks, and project management. His recognitions include the UBC Department of Pathology 2010 Faculty Award for Excellence in Research and Discovery, and he has an extensive publication record including a widely read monthly serialized article “The Primer” on aspects of clinical molecular diagnostics, now in its third year of publication in Medical Laboratory Observer.

Dr. Kevin She

BA, MSc., Ph.D., Quality Assurance Manager/Senior Scientist

Dr. She has a diverse background including industrial microbiology for the discovery of novel antibiotics, extensive expertise in mammalian tissue and cell culture, and industrial experience in writing and implementing SOPs for products intended for use in the clinical setting. During his grant funded industrial postdoctoral fellowship, Dr. She has written SOPs for the use, production, quality control, test validation, and real-time product stability testing for molecular diagnostic kits intended for use in the clinical setting. In addition to implementing these SOPs, he has also trained and supervised others in the adherence to these protocols. Throughout his career, Dr. She has acquired a strong academic publishing portfolio and contributed to successful C17 and NIH R01 grants, among others, and has personally been awarded MSFHR, a prestigious CIHR CGS, and NSERC grants.

Dr. Kevin Mehr

B.Sc., Ph.D., Business Development

Dr. Mehr finished his Ph.D. in Genome Science and Technology at the University of British Columbia (UBC). He is an expert in the fields of Microbiology and Genomics, with over seven years of research lab experience and published articles. He has overseen multiple research projects during his graduate work, including the supervision of students and lab members. His research background includes topics such as developing analytical techniques for the isolation and detection of antibiotics, protein engineering of carbohydrate processing enzymes to improve activity, developing ultra high-throughput screening techniques for detecting and isolating sugar processing enzymes from environmental bacterial libraries, and developing technology for the functional display of enzymes on viral phage particles for improving enzymatic activity. Recently he also developed a method to detect fusarium infections in Cannabis spp. plants.

Christine Thomson

Corporate Secretary

Ms. Thomson has 20 years of experience in the securities market including 12 years direct experience acting as an officer and or director providing corporate secretary services to listed companies. This experience includes working with highly active and successful companies listed on the TSX, TSX.V, NYSE and the Alternative Investment Market of the London Stock Exchange.

Ying Ng

Molecular Biology Lab Manager

Ms. Ng obtained her B.Sc. in Molecular Biology and Biochemistry from Simon Fraser University, followed by the Registered Technologist (CSMLS) program in Clinical Genetics from the British Columbia Institute of Technology. Working at BC Provincial Health Services Authority (PHSA) for over 12 years, she started as a clinical molecular and cytogenetics technologist. In 2011, she obtained formal certification in biobanking and led the biobanking efforts for the BC Cancer Agency and Vancouver General Hospital. In 2013 she completed her M.A. in Leadership from Trinity Western University. Most recently prior to joining Segra, her role in PHSA was as a lab manager where she oversaw facility planning of laboratory space, acquired capital equipment, and ensured proper resourcing of multiple projects.

Prabhleen Kaur

Senior Tissue Culture Specialist

Ms. Kaur is a highly technical and efficient tissue culture specialist who has studied under the tutelage of Dr. Zobayed for the past five years. She received her Diploma in Production Horticulture in 2015 from Kwantlen Polytechnic University. From there she achieved her Certification on Photoautotrophic Tissue Culture from the Faculty of Horticulture at Chiba University in Japan and Certification on Micropropagation Techniques from Nerang MDC in Australia. She began her career in 2011 as a Quality Control Technician at Lally Farms in Abbotsford, BC, and was then hired at JRT Nurseries, in Aldergrove, BC, as the Plant Tissue Culture Supervisor. She has held positions of increasing responsibility at JRT Nurseries, where she most recently held the position of Assistant Manager for the Tissue Culture Labs in Washington State and BC, that have a maximum output of 12 million plants a year for over 500 different plant species.